| Literature DB >> 35794560 |
Weiwei Zeng1,2, Sixian Lao3,4, Wenbin Jia2, Xintian Shen2, Lijuan Wu2, Yan Zhong5, Feiling Wang6, Guoping Zhong7,8.
Abstract
BACKGROUND: Few studies have investigated the differences in clinical features of patients with mastitis following Corynebacterium kroppenstedtii infection, and most focused on the bacterial antimicrobial susceptibility, detection methods and therapy.Entities:
Keywords: Antibiotics; Clinical features; Corynebacterium kroppenstedtii; Granulomatous lobular mastitis; Treatment
Mesh:
Substances:
Year: 2022 PMID: 35794560 PMCID: PMC9258122 DOI: 10.1186/s12905-022-01859-y
Source DB: PubMed Journal: BMC Womens Health ISSN: 1472-6874 Impact factor: 2.742
Fig. 1Corynebacterium kroppenstedtii after isolated and subculture on sheep blood agar at 48 h
Clinical characteristics of patients infected by Corynebacterium kroppenstedtii
| Characteristic | N = 133 | NGLM (n = 75) | GLM (n = 57) | |
|---|---|---|---|---|
| (All were female patients) | (Exclude one lactation mastitis patients) | |||
| Age in years, median (range) | 32 (11–56) | 31 (29–34) | 32 (29–35) | 0.43 |
| Weight in kg, median (range) | 59.8 (43.0–88.0); n = 98 | 58.0 (52.5–64.5); n = 41 | 57.8 (53.0–66.0); n = 56 | 0.88 |
| BMI in kg/m2, median (range) | 23.0 (16.8–32.4);n = 62 | 22.1 (20.3–25.0); n = 20 | 22.5 (20.9–24.9); n = 41 | 0.12 |
| Low weight, < 18.5 | 1 (1.6%) | 0 (0.0%) | 1 (2.4%) | |
| Normal weight, 18.5–24 | 40 (59.7%) | 10 (50.0%) | 30 (73.2%) | |
| Obesity, ≥ 24 | 21 (38.7%) | 10 (50.0%) | 10 (24.4%) | |
| Clinical presentation | ||||
| Nonlobular granulomatous mastitis | 76 (57.1%) | |||
| Lobular granulomatous mastitis | 57 (42.9%) | |||
| Laterality | n = 133 | 0.74 | ||
| Left | 63 (47.4%) | 33 (44.0%) | 29 (50.9%) | |
| Right | 60 (45.1%) | 36 (48.0%) | 24 (42.1%) | |
| Bilateral | 10 (7.5%) | 6 (8.0%) | 4 (7%) | |
| Symptoms | ||||
| Pain | 120 | 68 (89.5%) | 52 (91.2) | 0.74 |
| Pus | 52 | 43 (56.0%) | 19 (33.3%) | 0.01* |
| Mass | 131 | 74 (97.4%) | 57 (100.0%) | 0.61 |
| Two or more of the above symptoms | 127 | 74 (94.9%) | 55 (96.5%) | 0.65 |
| WBC, × 109/L | 9.3 (4.1–18.7); n = 107 | 8.95 (6.81–11.05) | 8.95 (7.45–11.05) | 0.74 |
| NEUT, × 109/L | 7.3 (2.0–78.4); n = 106 | 5.75 (4.39–8.16) | 6.40 (5.11–8.43) | 0.27 |
| LYMPH, × 109/L | 2.03 (0.58–16.30); n = 106 | 1.85 (1.43–2.29) | 1.69 (1.38–2.17) | 0.45 |
| CRP, mg/L | 15.9 (0.5–109.4); n = 66 | 6.05 (4.10–33.40) | 12.50 (1.50–10.30) | 0.03* |
| Medical History | ||||
| Hypertension | 1 | 0 | 1 | |
| Mammary gland tumor | 3 | 1 | 2 | |
| Depression | 1 | 0 | 1 | |
| Childbirth history | n = 116 | 0.68 | ||
| 0 | 4 | 2 (3.3%) | 2 (3.6%) | |
| 1 | 71 | 34 (56.7%) | 37 (67.3%) | |
| 2 | 36 | 21 (35.0%) | 14 (25.5%) | |
| 3 | 5 | 3 (5.0%) | 2 (3.6%) | |
| History of lactation in months, median (range) 10.5 (0–48); n = 110 | 0.15 | |||
| < 12 | 70 | 33 (61.1%) | 37 (67.3%) | |
| 12–24 | 32 | 19 (35.2%) | 12 (21.8%) | |
| > 24 | 8 | 2 (3.7%) | 6 (10.9%) | |
| Clinical Treatment with Medications | n = 114 | < 0.01* | ||
| Steroid | 22 | 9 (16.7%) | 13 (22.0%) | |
| Antibiotic | 56 | 40 (74.1%) | 15 (25.4%) | |
| Steroid and antibiotic | 36 | 5 (9.3%) | 31 (52.3%) | |
| Invasive Clinical Treatment | n = 64 | 0.01* | ||
| Punctures | 29 | 7 (38.9%) | 22 (48.9%) | |
| Drainage | 13 | 8 (44.4%) | 5 (11.1%) | |
| Punctures and drainage | 22 | 3 (16.7%) | 18 (40.0%) | |
| Recurrence | n = 105 | 0.90 | ||
| 0 | 59 | 28 (58.3%) | 30 (53.6%) | |
| 1 | 32 | 13 (27.1%) | 19 (33.9%) | |
| 2 | 10 | 5 (10.4%) | 5 (8.9%) | |
| ≥ 3 | 4 | 2 (4.2%) | 2 (3.6%) | |
WBC white cell count, NEUT neutrophil granulocyte, LYMPH lymphocyte, CRP C-reactive protein, GLM granulomatous lobular mastitis, NGLM non-granulomatous lobular mastitis
*p < 0.01 which means there is significant difference between groups
The recurrence of different treatment groups
| Treatment group | Without recurrence (%) | Recurrence (%) | χ2 | |
|---|---|---|---|---|
| Steroid | 17 (51.5) | 16 (48.5) | 4.83 | 0.09 |
| Antibiotic | 36 (75.0) | 12 (25.0) | ||
| Steroid and antibiotic | 28 (62.2) | 17 (37.8) |
Fig. 2The recurrence of mastitis treated with different antibiotics a or steroid and antibiotics b. Cefuroxime*: Cefuroxime + doxycycline or ceftriaxone or ciprofloxacin; T + C: triamcinolone acetonide + gentamicin; T + L: triamcinolone acetonide + levofloxacin; T + G: triamcinolone acetonide + cefuroxime
The multivariable analysis of laboratory test result between groups
| Variables | NGLM | GLM | Multivariable | |||
|---|---|---|---|---|---|---|
| n | n | OR | 95% CI | |||
| Lower | Upper | |||||
| White cell count | 57 | 49 | 0.75 | 0.34 | 1.69 | 0.49 |
| Neutrophil granulocyte | 57 | 48 | 1.37 | 0.55 | 3.44 | 0.50 |
| Lymphocyte | 66 | 39 | 0.85 | 0.50 | 1.44 | 0.54 |
| C-reactive protein | 38 | 27 | 1.00 | 1.00 | 1.03 | 0.81 |
GLM granulomatous lobular mastitis, NGLM non-granulomatous lobular mastitis,CI
Antimicrobial intermediary and antimicrobial susceptibilities of 56 patients
| Drug | Susceptible % | Intermediate % | Resistant % | MIC50 | MIC90 | Breakpoint |
|---|---|---|---|---|---|---|
| Vancomycin | 100 (49/49) | 0.00 (49/49) | 0.00 (49/49) | 0.5 | 0.5 | S ≤ 2 |
| Linezolid | 100 (38/38) | 0.00 (38/38) | 0.00 (38/38) | 0.25 | 0.5 | S ≤ 2 |
| Rifampin | 100 (27/27) | 0.00 (27/27) | 0.00 (27/27) | 0.008 | 0.008 | S ≤ 1, R ≥ 4 |
| Meropenem | 87.50 (42/48) | 4.17 (2/48) | 8.33 (4/48) | 0.064 | 0.5 | S ≤ 0.25, R ≥ 1 |
| Gentamicin | 94.12 (32/34) | 0.00 (0/34) | 5.88 (2/34) | 0.125 | 0.5 | S ≤ 4, R ≥ 16 |
Trimethoprim -sulfamethoxazole | 77.36 (41/53) | 0.00 (0/53) | 22.64 (12/53) | 0.25 | 32 | S ≤ 2/38, R ≥ 4/76 |
| Ciprofloxacin | 69.09 (38/55) | 0.00 (0/55) | 30.91 (17/55) | 0.25 | 32 | S ≤ 1, R ≥ 4 |
| Ceftriaxone | 50.00 (28/56) | 14.29 (8/56) | 35.71 (20/56) | 1 | 8 | S ≤ 1, R ≥ 4 |
| Tetracycline | 41.46 (17/41) | 48.78 (20/41) | 9.76 (4/41) | 8 | 8 | S ≤ 4, R ≥ 16 |
| Clindamycin | 23.26 (10/43) | 0.00 (0/43) | 76.74 (33/43) | 256 | 256 | S ≤ 0.5, R ≥ 4 |
| Erythromycin | 19.64 (11/56) | 1.79 (1/56) | 78.57 (44/56) | 16 | 256 | S ≤ 0.5, R ≥ 2 |
| Penicillin | 0.00 (0/56) | 89.29 (50/56) | 10.71 (6/56) | 0.5 | 2 | S ≤ 0.12, R ≥ 4 |
MIC: minimum inhibitory concentration